Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin)

Acta Anaesthesiologica Scandinavica

Volumn 57, Issue 5, 2013, Pages 565-572

  Rosencher, N ^a   Llau, J V ^b   Mueck, W ^c   Loewe, A ^c   Berkowitz, S D ^d   Homering, M ^c  

^a Paris Descartes University ^*  (France)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c BAYER PHARMA AG   (Germany)

^d BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ENOXAPARIN; PLACEBO; RIVAROXABAN;

ADULT; AGED; ANESTHESIA; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; DRUG SAFETY; EPIDURAL CATHETER; FEMALE; GENERAL ANESTHESIA; HEMATOMA; HUMAN; KIDNEY FAILURE; KNEE ARTHROPLASTY; LAMINECTOMY; LUNG EMBOLISM; MALE; NEURAXIAL ANESTHESIA; NEURAXIAL HEMATOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINAL ANESTHESIA; SPINAL CORD HEMORRHAGE; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ENOXAPARIN; FEMALE; HEMATOMA; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84876285885     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12069     Document Type: Article

References (18)

1. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004; 101: 950-9.
2. Rosencher N, Bonnet MP, Sessler DI. Selected new anti-thrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia 2007; 62: 1154-60.
3. Breivik H, Bang U, Jalonen J, Vigfússon G, Alahuhta S, Lagerkranser M. Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Acta Anaes-thesiol Scand 2010; 54: 16-41.
4. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Missel-witz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthro-plasty. N Engl J Med 2008; 358: 2765-75.
5. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-9.
6. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thrombo-prophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-86.
7. Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophy-laxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-80.
8. Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SL, Benzon HT, Brown DL, Heit JA, Mulroy MF, Rosenquist RW, Tryba M, Yuan CS. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (third edition). Reg Anesth Pain Med 2010; 35: 64-101.
9. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaes-thesiology. Eur J Anaesthesiol 2010; 27: 999-1015.
10. Llau Pitarch JV, De Andrés Ibáñez J, Gomar Sancho C, Gómez Luque A, Hidalgo Martínez F, Torres Morera LM. [Hemostasis-altering drugs and regional anesthetic techniques: safety guidelines]. Rev Esp Anestesiol Reanim 2004; 51: 137-42.
11. VandermeulenE, SingelynF, VercauterenM, Brichant JF, Ickx BE, Gautier P. Belgian guidelines concerning central neural blockade in patients with drug-induced alteration of coagulation: an update. Acta Anaesthesiol Belg 2005; 56: 139-46.
12. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983; 249: 1743-5.
13. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225-31.
14. Kubitza D, Becka M, MueckW, Halabi A, Maatouk H, Klause N, Lufft V, Wand DD, Philipp T, Bruck H. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban-an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70: 703-12.
15. Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, Van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011; 104: 669-76.
16. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74-81.
17. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-99.
18. Rosencher N, Vielpeau C, Emmerich J, Fagnani F, Samama CM. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost 2005; 3: 2006-14.